Synergestic effect of coenzyme Q10 and magnesium sulphate in reducing myocardial infarction caused by isoproterenol in rats

Arti Negi¹, Rajendra Sandur V²*, Nilanjan Ghosh¹, Nikitha Gavind²

¹ Department of Pharmacology and Toxicology, Guru Ram Das (P.G.) Institute of Management and Technology, Dehradun, India
² Krupanidhi College of Pharmacy, Bengaluru, India

Please cite this article as:

ABSTRACT

The objective of the study aims to evaluate the combined protective effects of coenzyme Q10 and magnesium sulphate on isoproterenol induced myocardial damage in rats. CoenzymeQ10 (50 mg/kg) and magnesium sulphate (10 mg/kg) were administered orally to wistar rats in individual or in combination for 30 days. At the end of this period, rats were administered isoproterenol (85 mg/kg i.p.) intraperitoneally for two consecutive days to induce myocardial injury. After induction, rats were anaesthetized and plasma was collected to analyze various biochemical parameters. Further, immunohistochemistry and histopathology of the heart tissue was performed. Induction of rats with isoproterenol resulted in a marked (p<0.001) elevation of infarct size, level of serum marker enzymes (AST, ALT, LDH and CK-MB), lipid peroxidation, protein expression of alpha-smooth muscle actin (αSMA) along with alterations in histopathology. Pretreatment with combination of coenzyme Q10 (CoQ10) and magnesium sulphate (MgSO4) exhibited a significant (p<0.001) decrease in serum marker enzyme, infarct size, lipid peroxidation, protein expression of α-smooth muscle actin (α-SMA) and showed preservation of cardiomyocytes histo-architecture when compared with individual treated groups. This study demonstrated the synergistic cardio protective effect of coenzymeQ10 (CoQ10) and magnesium Sulphate (MgSO4) in isoproterenol induced myocardial damage in rats demonstrated that the oral pre-treatment with CoQ10 and Magnesium sulphate were associated with moderate protection against ISO-induced cardio toxicity and cardiac hypertrophy. The mechanism might be associated with the enhancement of antioxidant defense system. The present results can form the basis that combination of CoQ10 and magnesium sulphate proved to be a potential therapeutic agent for pharmacological management of ischemic heart disease. It could provide experimental evidence to support the rationality of combinatorial use in the prevention of the onset and progression of myocardial injury.

Conflicts of Interest: Declared None
Funding: None

INTRODUCTION

Cardiovascular disease (CVD), predominantly myocardial damage, is the leading cause of death worldwide [1]. Acute myocardial damage is the most important and serious consequence of coronary artery disease. It occurs
when myocardial ischemia, a diminished blood supply to heart, exceeds a critical threshold and overwhelms myocardial cellular repair mechanisms designed to maintain normal operating function and homeostasis. Ischemia at this critical threshold level for an extended period results in irreversible myocardial cell damage or death [2]. According to W.H.O., 17.3 million deaths in 2008 were attributed to cardiovascular disease, with 7.3 million (42 % of all cardiovascular deaths) being due to the result of a myocardial damage [3]. In India, 31.7 % of deaths occur due to MI. Incidence of cardiovascular diseases was about 7 % in 970 and increase up to 32 % in 2011 in India [4]. Myocardial damage is invariably followed by numerous pathophysiological and biochemical alterations including hyperlipidemia, thrombosis, lipid peroxidation (LPO) and free radicle damage etc., leading to qualitative and quantitative changes of myocardium [5]. Isoproterenol is a synthetic catecholamine and β-adrenergic agonist which has been documented to produce severe stress in the myocardium resulting in myocardial damage, if administered in supramaximal doses [6, 7].

The pathophysiological and morphological aberrations produced in the heart of this myocardial necrotic rat model are comparable with those taking place in human. Among the various mechanism proposed to explain ISO induced damage to cardiac myocytes including hypoxia, coronary hypotension, calcium overload, energy depletion and excessive production of free radicals as a result of catecholamine auto-oxidation [7]. Various experimental and clinical studies have shown that enormous amount of reactive oxygen species such as superoxide, hydrogen peroxide and hydrogen radicals are generated in failing myocardium [8]. CoQ10 (ubiquinone, CoQ10) is ubiquitous and has a central role against the depletion of ATP (Adenosine tri phosphate) as an electron carrier in the mitochondrial respiratory chain and in oxidative phosphorylation. Extra mitochondrial CoQ10 is also an efficient lipid soluble antioxidant, protecting against lipid peroxidation [9]. Low levels of cardiac CoQ10 is observed in patients with cardiomyopathy [10]. Coenzyme Q10 exerts action at the cellular level and rectifies some of the basic deficiencies leading to aggravation of heart related diseases [11]. These cardio protective effects of CoQ10 are most likely explained by its antioxidant effect and its ability to generate ATP which requires continuous reduction of ubiquinone and regeneration to the active ubiquinol form [12].

Magnesium, a rare alkaline earth metal is the second most abundant intracellular cation and the fourth most important cation in the body [13]. Magnesium is critical for the proper functioning of many physiologic reactions, including those that are critical to the cardiovascular system. Magnesium deficiency has been suggested in cardiomyopathy [14]. Also, there is growing evidence that magnesium status is important in pathogenesis and treatment of cardiovascular disease [15]. Calcium overload is central in ischemic myocardial cell death and this is exacerbated during reperfusion. Magnesium administration may provide cellular protection during ischemia. Magnesium drives calcium into the sarcoplasmatic reticulum, reduces mitochondrial calcium overload [16] and competes with calcium for binding to troponin C. It also inhibits calcium influx into myocytes band thus prevents increase in intracellular concentration of calcium function. Magnesium helps to conserve ATP as the magnesium salt [17]. The present study is designed to evaluate the preventive effect on architectural alteration in myocardial tissue through Anti-α smooth muscle actin (α-SMA) by using a combination of CoenzymeQ10 with Magnesium Sulphate on β adrenergic stimulator induced myocardial injury.

**MATERIALS AND METHODS**

**In vivo study**

Animals: All experiments and protocols described in the present study were approved by the Institutional Animal Ethics Committee (IAEC) of Pharmacy Department and Committee for the purpose of Control and Supervision of Experiments on animals (CPCSEA) guidelines (IAEC Approval Number:- 1145/07/CPCSEA, Date:- 15/12/2013). Rats of both sexes, weighing about 200-250 g were obtained from SGR Institute of Technology, Dehradun. The animals were housed in separate cages and maintained under standardized condition (25±5°C and 35 to 60 % humidity ) in a well-ventilated animal house under 12 hour light-dark cycle. They were provided free access to standard laboratory food and purified drinking water *ad libitum.*

**Induction of experimental myocardial damage**

Isoproterenol was dissolved in normal saline and injected intraperitoneally to rats (85 mg/kg, i.p.) at an interval of 24 h for 2 days to induce experimental myocardial damage [18, 19].

**Experimental Design**

After acclimatization, animals were randomly divided into the following groups consisting of 6 rats each:

- **Group I (Control):** Animals received standard laboratory diet and drinking water *ad libitum* and served as a control group.
- **Group II (Positive control):** Animals received isoproterenol (85 mg/kg, i.p) for 2 days.
- **Group III (Coenzyme):** Animals received CoQ10 (50 mg/kg) orally daily for 30 days and isoproterenol on 31st and 32nd day and then treatment were continued for 10 days.
- **Group IV (MgSO4):** Animals received MgSO4 (10 mg/kg) orally daily for 30 days and isoproterenol on 31st and 32nd day and then treatment were continued for 10 days [20].
- **Group V (CoQ10 and MgSO4):** Animals received combination of CoQ10 + MgSO4 (50 mg/kg +10 mg/kg), orally daily for 30 days and isoproterenol on 31st and 32nd day and then treatment were continued for 10 days [21, 22].

**In vitro antioxidant study**

**Reducing power activity**

Principle: This method is based on the principle of

---

**Iranian J Pharmacol Ther. 2018 (April);16:1-9.**

This paper is available online at: http://ijpt.iums.ac.ir
increase in the absorbance of the reaction mixtures. Increase in the absorbance indicates an increase in the antioxidant activity. Increase in absorbance of the reaction mixture indicates the reducing power of the samples. Substances, which have reduction potential, react with potassium ferricyanide (K₃Fe(CN)₆) (Fe³⁺) to form potassium ferrocyanide (Fe⁺), which then reacts with ferric chloride to form ferric ferrous complex that has an absorption maximum at 700 nm.

Potassium ferricyanide + Ferric chloride → Potassium ferrocyanide + ferrous chloride

Procedure: In this method, antioxidant compound forms a colored complex with potassium ferricyanide, trichloroacetic acid and ferric chloride, which is measured at 700 nm. Increase in absorbance of the reaction mixture indicates the reducing power of the samples. In the method 2.5 ml of 0.2 M phosphate buffer (pH 6.6) and 2.5 ml of K₃Fe(CN)₆ (1 % w/v) were added to different conc. of drug sample dissolved in distilled water. The resulting mixture was incubated at 50 ºC for 20 min, followed by the addition of 2.5 ml of trichloroacetic acid (10 % w/v). The mixture was centrifuged at 3000 rpm for 10 min to collect the upper layer of the solution. Then 2.5 ml of supernatant was mixed with 2.5 ml distilled water and 0.5 ml of ferric chloride (0.1 % w/v). The absorbance was measured at 700 nm against blank sample [23].

Body weight and Heart weight: The body weights of rat were monitored at regular intervals during the experimental period. At the end of the experiment, the animals were euthanized, the hearts were removed, weighed, and histological examinations were done. The relative heart weight to body weight ratio was calculated to assess the degree of myocardial weight gain [24].

Biochemical parameters in serum: The collected serum was used for the estimation of cardiac marker creatine kinase-MB (CK-MB) [25], lactate dehydrogenase (LDH) [26,27], aspartate transaminase (AST) and alanine transaminase (ALT) [28] using commercially available standard enzymatic Ranbaxy kits.

Measurement of Myocardial infarct size: The principle of tri phenyl tetrazolium chloride (TTC) assay is based on the oxidation of TTC by the intact mitochondrial dehydrogenase, which results in the formation of 1,3,5-triphenyltetrazolium formazan (carmin red product). Infarcted tissues lack dehydrogenase activity and hence no stain is observed [29, 30].

The heart was transversely cut across the left ventricle, and sections having 2mm to 3mm thickness were incubated in 1 % TTC solution prepared in phosphate buffer for 30 min at 37 ºC. Later tissues were fixed in 10 % formalin. The non-ischemic myocardium and viable ischemic myocardium were stained red, while the infarcted myocardium were observed as pale grey or white [31].

In vivo Lipid peroxidation

This assay is based on the reaction of a chromogenic reagent, 2-thiobarbituric acid, with malondialdehyde (MDA) at 25 ºC which results in the formation of a chromophore with absorbance maxima at 530 nm. Determinations of lipid peroxidation were done by colorimetric estimation by measuring the amount of malondialdehyde (MDA) [32]. Samples were homogenized in cold phosphate buffer saline (pH-7.4). To 2 ml of the above sample, 2 ml of 28 % trichloroacetic acid were added and centrifuged. To the above 4 ml of supernatant 1 ml of 1 % thiobarbituric acid was added, and heated in boiling water for 60 min. The solution was cooled. The absorbance of the solution was then read using a spectrophotometer at 530 nm [33]. The amount of malondialdehyde (MDA) (nmol/mL) was then calculated.

Histopathological examination

Rats were sacrificed and hearts were collected from each group. The myocardial tissues were preserved in natural phosphate buffer, 10 % formalin solution for histological studies. Haemotoxylin and Eosin (H&E) stains were used to stain the sections for histological evaluation using light microscope [34].

Immunohistochemistry

The paraffin sections were deparaffinized in xylene, dehydrated in a graded series of ethanol. Sections were then incubated in antigen for retrieval (boiling the section at 98 ºC for 20 minutes in 10 mM/L sodium citrate buffer) and then treated with 3 % H₂O₂. Monoclonal antibody α smooth muscle actin (α-SMA) were applied on the slide and incubated in humid chamber overnight in a refrigerator at 4 ºC. Secondary antibodies were then applied followed by incubation with streptavidin peroxidase. Sections were washed with phosphate buffered saline (PBS) three times after each step. Sections were then stained with diaminobenzidine (DAB) chromogenic solution and counter stained with haemotoxylin [35].

Statistical Analysis

The results were expressed as mean ± standard deviation for six rats for each group. The statistical analyses were performed using Graph Pad Prism software version 5.04 statistical package program. Analyses were done using one-way analysis (ANOVA) followed by Dunnett’s multiple comparison tests. P value < 0.05 was considered statistically significant.

RESULTS

In vitro antioxidant activity

Reducing power activity

It was observed that the CoQ10 have demonstrated dose dependent increase in the reducing property. Ethanolic solution of CoQ10 (100 mg) have shown maximum reducing power i.e. 95.70 % at concentration of 100 mg/mL and ascorbic acid have shown maximum activity i.e. 134.49 % at concentration 100 µg/mL. However, Magnesium sulphate does not show any reducing power activity. But reducing power activity increased when both CoQ10 and MgSO₄ used
The heart weight and the heart weight to body weight ratio were slightly reduced in body weight compared to the control group as shown in Table 2. There was no significant difference in the body weight between the groups observed, although isoproterenol treated animals showed a slight reduction in body weight which was not significant. The heart weight and the heart weight to body weight ratio was increased significantly (p<0.001) in isoproterenol-administered rats as compared to control rats. However, rats pretreated with CoQ10 and Magnesium sulphate treatment show significant decrease in the heart weight/body weight ratio when compared to Isoproterenol treated group.

**Effect of CoQ10 and magnesium sulphate on cardiac marker enzymes**

The effects of CoQ10, magnesium sulphate and isoproterenol treatment on cardiac marker enzymes are depicted below. The levels of cardiac marker enzymes AST, ALT, LDH and CK-MB were significantly increased in the serum of Isoproterenol administered rats in comparison with control group. Pretreatment with CoQ10 and Magnesium sulphate treatment showed significant decrease in the serum levels of these enzymes compared to control and isoproterenol treated group.

**Table 1. Reducing power activity of Ascorbic acid, CoQ10 and CoQ10+MgSO4**

<table>
<thead>
<tr>
<th>S. No.</th>
<th>Conc. (µg/ml)</th>
<th>Abs (Ascorbic acid)</th>
<th>% Increase in reducing activity (Ascorbic acid)</th>
<th>Conc. (mg/ml)</th>
<th>Abs (CoQ10)</th>
<th>% Increase in reducing activity (CoQ10)</th>
<th>Abs CoQ10 + MgSO4</th>
<th>% Increase in reducing activity (CoQ10 + MgSO4)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>1.56</td>
<td>0.423</td>
<td>4.96%</td>
<td>1.56</td>
<td>0.526</td>
<td>2.73%</td>
<td>0.623</td>
<td>10.26%</td>
</tr>
<tr>
<td>2</td>
<td>3.125</td>
<td>0.475</td>
<td>17.86%</td>
<td>3.125</td>
<td>0.598</td>
<td>16.79%</td>
<td>0.687</td>
<td>21.59%</td>
</tr>
<tr>
<td>3</td>
<td>6.25</td>
<td>0.514</td>
<td>27.54%</td>
<td>6.25</td>
<td>0.630</td>
<td>23.04%</td>
<td>0.795</td>
<td>40.70%</td>
</tr>
<tr>
<td>4</td>
<td>12.5</td>
<td>0.597</td>
<td>48.13%</td>
<td>12.5</td>
<td>0.680</td>
<td>32.81%</td>
<td>0.824</td>
<td>45.84%</td>
</tr>
<tr>
<td>5</td>
<td>25</td>
<td>0.654</td>
<td>62.28%</td>
<td>25</td>
<td>0.724</td>
<td>41.40%</td>
<td>0.899</td>
<td>59.11%</td>
</tr>
<tr>
<td>6</td>
<td>50</td>
<td>0.756</td>
<td>87.59%</td>
<td>50</td>
<td>0.812</td>
<td>58.59%</td>
<td>0.989</td>
<td>75.04%</td>
</tr>
<tr>
<td>7</td>
<td>100</td>
<td>0.945</td>
<td>134.49%</td>
<td>100</td>
<td>1.002</td>
<td>95.70%</td>
<td>1.234</td>
<td>118.4%</td>
</tr>
</tbody>
</table>

**Table 2. Effect of CoQ10 & Magnesium Sulphate pretreatment on heart weight, body weight and heart weight/body weight ratio in isoproterenol induced myocardial damage in rats**

<table>
<thead>
<tr>
<th>Groups</th>
<th>Control</th>
<th>ISO-treated</th>
<th>CoQ10+ISO</th>
<th>MgSO4+ISO</th>
<th>CoQ10+MgSO4 + ISO</th>
</tr>
</thead>
<tbody>
<tr>
<td>Initial body weight (g)</td>
<td>252±1.51</td>
<td>240.2±2.34</td>
<td>245.4±2.17</td>
<td>245±1.83</td>
<td>250±0.02</td>
</tr>
<tr>
<td>Body weight (g)</td>
<td>252±1.67</td>
<td>232.6±2.94*</td>
<td>242.16±2.48*</td>
<td>240.16±1.16*</td>
<td>247.16±1.16*</td>
</tr>
<tr>
<td>Heart weight (g)</td>
<td>0.603±0.1</td>
<td>1.065±0.02*</td>
<td>0.822±0.01*</td>
<td>0.878±0.015*</td>
<td>0.744±0.02*</td>
</tr>
<tr>
<td>Heart weight to body weight ratio (%)</td>
<td>0.239±0.008</td>
<td>0.457±0.01*</td>
<td>0.338±0.006*</td>
<td>0.36±0.006*</td>
<td>0.303±0.006*</td>
</tr>
</tbody>
</table>

All values are expressed as mean ± S.D. (n=6). *P<0.05, P<0.001 vs. Control; #P<0.05, P<0.001 vs. ISO; @P<0.05, P<0.001 vs. CoQ10+ISO; ^P<0.05, P<0.001 vs. MgSO4+ ISO (one way ANOVA).

**Table 3. Serum marker level in all groups before induction of myocardial damage**

<table>
<thead>
<tr>
<th>Groups</th>
<th>Control</th>
<th>ISO</th>
<th>CoQ10+ISO</th>
<th>MgSO4+ISO</th>
<th>CoQ10+MgSO4 + ISO</th>
</tr>
</thead>
<tbody>
<tr>
<td>AST (U/L)</td>
<td>68.8±2.22</td>
<td>66.3±1.89</td>
<td>66.83±1.91</td>
<td>74.18±1.84</td>
<td>57.46±1.93</td>
</tr>
<tr>
<td>ALT (U/L)</td>
<td>34.90±2.40</td>
<td>35.50±1.76</td>
<td>43.28±0.99</td>
<td>37±2.36</td>
<td>35.08±2.65</td>
</tr>
<tr>
<td>LDH (U/L)</td>
<td>126.93±0.88</td>
<td>123.66±2.65</td>
<td>125.51±2.27</td>
<td>128.5±1.87</td>
<td>123.75±2.28</td>
</tr>
<tr>
<td>CK-MB (IU/L)</td>
<td>116.5±1.43</td>
<td>118.5±3.39</td>
<td>111.16±2.69</td>
<td>125.66±2.73</td>
<td>114.16±3.06</td>
</tr>
</tbody>
</table>

**Table 4. Effect of CoQ10 and Magnesium sulphate on cardiac marker enzymes**

<table>
<thead>
<tr>
<th>Groups</th>
<th>Control</th>
<th>ISO-treated</th>
<th>CoQ10+ISO</th>
<th>MgSO4+ISO</th>
<th>CoQ10+MgSO4 + ISO</th>
</tr>
</thead>
<tbody>
<tr>
<td>AST (U/L)</td>
<td>67.70±2.14</td>
<td>166±3.27*</td>
<td>107.44±2.68*</td>
<td>118.78±3.33*</td>
<td>84.59±2.95*</td>
</tr>
<tr>
<td>ALT (U/L)</td>
<td>35.20±1.63</td>
<td>74.39±2.31*</td>
<td>56.60±1.41*</td>
<td>63.58±2.32*</td>
<td>50.77±1.32*</td>
</tr>
<tr>
<td>LDH (U/L)</td>
<td>128.91±3.03</td>
<td>280.22±14.1*</td>
<td>172.05±2.10*</td>
<td>182.54±3.18*</td>
<td>144.82±4.12*</td>
</tr>
<tr>
<td>CK-MB (IU/L)</td>
<td>121.64±2.82</td>
<td>307.43±11.1*</td>
<td>162.65±3.20*</td>
<td>161.17±4.04*</td>
<td>135.07±1.24*</td>
</tr>
</tbody>
</table>

Results are expressed as mean ± S.D. (n=6). *P<0.001 vs. Control; #P<0.0001 vs. ISO; @P<0.001 vs. CoQ10+ISO; ^P<0.0001 vs. MgSO4+ ISO (one way ANOVA).
Synergetic effect of coenzyme Q10 and magnesium sulphate in reducing myocardial infarction…

Measurement of myocardial infarct size

Representative illustrations of damage size using TTC staining are shown in Figure 1 and Table 5. ISO administration indicated a large unstained area with more necrotic patches. However, the heart slice of the CoQ10+ MgSO4+ ISO treated rats exhibited a major portion stained positively showing tissue viability with less necrotic tissues as compared to individual treated group. Figure 1 and also indicates the increased damage size in ISO administered group (52.48%), which were significantly (p<0.001) reduced to 21.61% with the combined pretreatment of CoQ10 and Magnesium sulphate.

Table 5. Effect of CoQ10 & Magnesium sulphate pretreatment on % infarct size

<table>
<thead>
<tr>
<th>S.No.</th>
<th>Groups</th>
<th>%Infarct size</th>
</tr>
</thead>
<tbody>
<tr>
<td>1.</td>
<td>Control</td>
<td>No damage</td>
</tr>
<tr>
<td>2.</td>
<td>ISO-treated*</td>
<td>52.48%</td>
</tr>
<tr>
<td>3.</td>
<td>CoQ10+ISO#</td>
<td>33.32%</td>
</tr>
<tr>
<td>4.</td>
<td>MgSO4+ISO#</td>
<td>46.13%</td>
</tr>
<tr>
<td>5.</td>
<td>CoQ10+ MgSO4+ISO##</td>
<td>21.61%</td>
</tr>
</tbody>
</table>

All values are expressed as mean ± S.D. (n = 4).*P<0.05 vs. Control;# P<0.05 vs. ISO;@ P<0.05 vs. CoQ10+ISO;^ P<0.05 vs. MgSO4+ ISO (one way ANOVA).

In vivo lipid peroxidation

To determine the lipid peroxidation, MDA levels were measured in serum and myocardial homogenates. Both serum and heart MDA levels were considerably increased (p<0.001) in isoproterenol alone treated rats in comparison with normal control group. However, treatment with CoQ10 and MgSO4 significantly reduced the rise of MDA levels of serum and myocardium. The value of MDA in serum and tissue were calculated from standard curve of MDA as indicated in Tables 6 and 7.

Effect of CoQ10 and Magnesium sulphate on histopathology of myocardium

Histopathological observation of normal control group

Table 6. Absorbance of serum and Heart tissue sample for lipid peroxidation assay

<table>
<thead>
<tr>
<th>S.No.</th>
<th>Groups</th>
<th>Serum Absorbance at 530nm</th>
<th>Heart Tissue Absorbance at 530nm</th>
</tr>
</thead>
<tbody>
<tr>
<td>1.</td>
<td>Control</td>
<td>0.428 0.398 0.456</td>
<td>0.123 0.182 0.165</td>
</tr>
<tr>
<td>2.</td>
<td>ISO-TREATED</td>
<td>1.982 1.894 1.858</td>
<td>0.836 0.891 0.848</td>
</tr>
<tr>
<td>3.</td>
<td>CoQ10+ISO</td>
<td>1.002 1.104 0.982</td>
<td>0.484 0.512 0.496</td>
</tr>
<tr>
<td>4.</td>
<td>MgSO4+ISO</td>
<td>1.412 1.346 1.432</td>
<td>0.652 0.576 0.656</td>
</tr>
<tr>
<td>5.</td>
<td>CoQ10+MgSO4+ISO</td>
<td>0.633 0.651 0.612</td>
<td>0.364 0.268 0.312</td>
</tr>
</tbody>
</table>

Figure 1. Images of heart slice showing extent of damage

Table 5. Effect of CoQ10 & Magnesium sulphate pretreatment on % infarct size

This paper is available online at: http://ijpt.iums.ac.ir
enlargement of cardiac cells and abundant fibroblastic hyperplasia along with increased edematous intramuscular space. The tissue sections from all treatment groups showed some infiltration with neutrophil granulocytes, interstitial edema and some discontinuity with adjacent myofibrils but the morphology of cardiac muscle fibers was relatively well preserved with no evidence of focal necrosis when compared to ISO induced group.

Combination of CoQ10 and MgSO4 showed a better morphology than individual treatment groups as clearly observed from Figure 2 and Table 8.

**IMMUNOHISTOCHEMISTRY**

The expression of α Smooth Muscle Actin (SMA) in the heart of normal and ISO administered rats are shown in Fig. 3. Immunohistochemical analysis showed that ISO injection significantly (p<0.05 or p<0.001) increased the expression of α Smooth Muscle Actin in the myocardium after 30th days, compared to control rats. That marker indicates the expression of high amount of stainable collagen with complex remodeling and reduplication of the collagen fiber network of the myofibril threads. Vimentin (pathological filamentous than initial days. Howevet, by the treatment of combination of CoQ10 and Magnesium sulphate the expression of α Smooth Muscle Actin (α-SMA) protein marker was down regulated (p<0.001), when compared to ISO groups.

**DISCUSSION**

Myocardial damage (MI) is major health problem and one of the leading causes of morbidity and mortality worldwide. MI occurs due to imbalance between myocardial blood supply and demand resulting in development of ischemia followed by necrosis [36]. Isoproterenol which is a synthetic catecholamine and β-adrenergic agonist, by its positive inotropic and chronotropic actions increases the myocardial oxygen demand that leads to ischemic necrosis [37].

In the present study, cardio protective effect of CoQ10 and CoQ10+ MgSO4 were evaluated by in vitro study and in vivo study. The antioxidative activity of CoQ10 and CoQ10+ MgSO4 were determined according to the reducing power method using spectrophotometer. It was observed that the CoQ10 have demonstrated dose dependent increase in the reducing property. In contrast, MgSO4 did not show any reducing power activity. However combination of both showed increase in percentage of reducing power activity.

Relative increase in heart weight is an index of cardiac hypertrophy. Hypertrophy observed is a compensatory response to necrosis of the heart muscle, caused by the severe stress of the heart induced by administration of ISO [38]. It may be due to the increase in overall protein biosynthesis during development of hypertrophy accompanied by edema or over expression of genes encoding proteins involved in the contractile unit [39]. The elevation of cytoplasmic calcium during MI could also be a factor responsible for the activation of intracellular signals governing the hypertrophic response of cardiac cells. Increase in heart weight might be attributed to increased

<table>
<thead>
<tr>
<th>S.No.</th>
<th>Groups</th>
<th>MDA content (nmol/ml serum)</th>
<th>MDA content (nmol/mg tissue)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1.</td>
<td>Control</td>
<td>5.32±0.40</td>
<td>1.56±0.42</td>
</tr>
<tr>
<td>2.</td>
<td>ISO-treated</td>
<td>25.91±0.88*</td>
<td>11.30±0.40*</td>
</tr>
<tr>
<td>3.</td>
<td>CoQ10+ISO</td>
<td>13.67±0.90*</td>
<td>6.29±1.96*</td>
</tr>
<tr>
<td>4.</td>
<td>MgSO4+ISO</td>
<td>18.74±0.61*</td>
<td>8.11±0.62*</td>
</tr>
<tr>
<td>5.</td>
<td>CoQ10+MgSO4+ISO</td>
<td>8.16±0.27*</td>
<td>3.77±0.69*</td>
</tr>
</tbody>
</table>

All values are expressed as mean ± S.D. (n=3). *P<0.05 vs. Control, # P<0.05, # P<0.001 vs. ISO. ** P<0.001 vs. CoQ10+ISO; ‹ P<0.001 vs. MgSO4+ISO (one way ANOVA).

<table>
<thead>
<tr>
<th>S.No.</th>
<th>Groups</th>
<th>Myonecrosis</th>
<th>Inflammation</th>
<th>Oedema</th>
</tr>
</thead>
<tbody>
<tr>
<td>1.</td>
<td>Control</td>
<td>++</td>
<td>+++</td>
<td>++++</td>
</tr>
<tr>
<td>2.</td>
<td>ISO-treated</td>
<td>+++</td>
<td>++</td>
<td>++</td>
</tr>
<tr>
<td>3.</td>
<td>CoQ10+ISO</td>
<td>++</td>
<td>++</td>
<td>+++</td>
</tr>
<tr>
<td>4.</td>
<td>MgSO4+ISO</td>
<td>+</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>5.</td>
<td>CoQ10+MgSO4+ISO</td>
<td>+</td>
<td>+</td>
<td>+</td>
</tr>
</tbody>
</table>

(+++++): severe; (+++): moderate; (+): mild; (–): nil
Synergestic effect of coenzyme Q10 and magnesium sulphate in reducing myocardial infarction...

Figure 2. Optical microscopic images of heart muscle, (Haemotoxylin and Eosin, presenting with Magnification10x100 and Magnification 40x100). A. Photomicrograph showing normal architecture of rat heart in control groups. B. Photomicrograph of rat heart of ISO treated group: a. subendocardial necrosis; b. increased edematous intramuscular space; c. fibroblastic hyperplasia; d. edema; Arrows represent prominent area of infiltrations of inflammatory cells. C. Photomicrograph of rat heart of CoQ10 treated group, showing less myocardial injury, less intramuscular space and inflammatory cells. Arrow represent prominent area of infiltrations of inflammatory cells. D. Photomicrograph of rat heart of MgSO4 treated group, showing less intramuscular space and inflammatory cells. a. infiltration of inflammatory cells; b. intramuscular space; Arrows represent infiltrations of inflammatory cells, and E. Photomicrograph of rat heart of CoQ10+MgSO4 treated group showing least myocardial injury, clear nuclear and myocytes architecture nearly similar to control group.

Figure 3. Immunohistochemical images of myocardium showing expression of α-Smooth Muscle Actin (α-SMA) (representing with Magnification10x100 and Magnification 40x100), * indicate expression of α-SMA. A. Immunohistochemical expression of α Smooth muscle actin (αSMA) in myocardium of Control group, B. Immunohistochemical expression of α Smooth muscle actin (αSMA) in myocardium of ISO-treated group, C. Immunohistochemical expression of α Smooth muscle actin (SMA) in myocardium of CoQ10 pretreated group, D. Immunohistochemical expression of α Smooth muscle actin (SMA) in myocardium of MgSO4 pretreated group, and E. Immunohistochemical expression of α Smooth muscle actin (SMA) in myocardium of CoQ10+MgSO4 pre-treated group.

Water content, edematous intramuscular space [40] and increased protein content. In the present study there has been significant increase in the heart weight and the heart weight to body weight ratio (i.e. Heart relative weight) in ISO induced rats. It is possible that CoQ10 improves cardiac bio energetic whereas Magnesium sulphate is natural calcium antagonist, thus reducing calcium overload during stress condition.

Myocardial cells contain several enzymes and macromolecules which on metabolic damage release the extracellular fluid and serve as diagnostic markers of myocardial injury [40]. The release of these enzymes reflects an alteration in the plasma membrane integrity and permeability in response to β-adrenergic stimulation. Measurement of AST, ALT, CK, and LDH activities is
necessary to ascertain extent of myocardial injury. In present study conducted, ISO administration caused a rise in the level of diagnostic marker enzymes AST, ALT, LDH, and CK due to leakage from tissue to blood serum as a result of damaged or destroyed cardiomyocytes, as well as, the cells damaged because of insufficient supply of oxygen and oxidative damage of myocardium which render the cell membrane fragile, porous, or ruptured. The increased levels of these enzymes are indicative of severity of cell necrosis and ISO mediated per oxidative myocyte injury. In this study, isoproterenol injected rats showed significant elevation in the levels of these marker enzymes in serum, and indicates ISO induced necrotic damage of the myocardium and leakiness of the plasma membrane. The combination of CoQ10 and Magnesium sulphate seems to preserve the structural and functional integrity and/or permeability of the cardiac membrane and thus restricting the leakage of these indicative enzymes as evident from the markedly decreased levels of these enzymes in CoQ10 + MgSO4 +ISO group when compared to the individual treatment groups, thereby establishing the cardio protective effect of the combination of CoQ10 and Magnesium sulphate.

Extent of myocardial damage was detected by direct staining with TTC dye. In the present study we observed an increased infarct size which is indicated by a clear bright/yellow color spot in the heart slices of ISO induced rats. The utilization of NADH by the free radicals produced by ISO and leakage of dehydrogenase enzymes from the damaged myocardial cells are the possible mechanisms that might prevented the conversion of TTC in to TPF. This may be the reason for the colorless bright spot in ISO induced rat heart and reflects the presence of non-viable cells. This finding was also supported by the increased levels of LDH in the serum of ISO induced rats, where LDH might release out from the myocardium. This ISO induced loss of dehydrogenases was counteracted by the co administration of CoQ10 & Magnesium sulphate. The increased damage area in ISO administered group (52.48%), which was significant (p<0.001) reduced to 21.61% with the combined pre-treatment of CoQ10 and MgSO4 further supporting the better protection from cardiac damage of the combination. This can be supported by the explanation that CoQ10 is a membrane stabilizer and preserves myocardial sodium-potassium ATPase activity and stabilizes myocardial calcium dependent ion channels, thus providing energy and enhancing contractile function in the failing heart. Also Magnesium has ability to inhibit myocardial cell sodium and calcium influx as well as potassium egress, thereby diminishing infarct-related reperfusion injury and limiting infarct size.

Lipid peroxidation is an important pathogenic event in MI and accumulation of oxidants makes the cell membranes more susceptible to oxidative injury and formation of lipid peroxidation product, MDA that reflects the damage of the myocardial cell contents. A significant increase in the levels of lipid peroxidation products in ISO induced rats appear to be the initial stage to the tissue making it more susceptible to oxidative damage. Increased production of free radicals may be responsible for the observed membrane damage as evidenced by the elevated lipid peroxidation in terms of TBARS in the present study. However, pre-treatment of rats with CoQ10 and MgSO4 significantly diminished cardiac tissue /serum MDA concentration which can be ascribed to the enhanced activities of antioxidant status in myocardium. MgSO4 can also reduce in vivo LPO possibly by reducing catecholamine’s secretion radicals. It has previously been shown that Mg blocks free radical formation both in cell cultures and in vivo [41]. Our study revealed that CoQ10 in combination with Magnesium sulphate had shown marked decreased in level of MDA thus mitigating lipid peroxidation.

Histopathological observation of normal control group exhibited clear integrity of myocardial membrane. Architectural changes found in Isoproterenol treated cardiomyocytes.

Stress induced hypertrophy creates structural alteration, subendocardial necrosis, infiltration of inflammatory cells and abundant fibroblastic hyperplasia along with increased edematous intramuscular space. The tissue sections from all treatment groups showed some infiltration with neutrophil granulocytes, interstitial edema and some discontinuity with adjacent myofibrils but the morphology of cardiac muscle fibers was relatively well preserved with no evidence of focal necrosis when compared to ISO induced group. Combination of CoQ10 and MgSO4 showed a better morphology than individual treatment groups.

Activation of fibroblast to myofibroblast is the hallmark of cardiac fibrosis. Immunohistochemical analysis confirms, above 90% of co-expressed α-SMA suggesting the activation of myofibroblast in Isoproterenol induce infarcted rat heart. In rat myocardial study the expression of α SMA was found in the spindle shaped cells. Expression of myofibroblast elevates the pressure overload of right ventricle. Isoproterenol induce group clearly indicates a heterogenous immunophenotype of myofibril, nuclear pigmentation and Vimatin expression staining through α SMA stain whereas CoQ10 with MgSO4 group shows significant reduction in the co expression of vimentin in the zone of expression. Further illustration of heterogeneity were characterized in myocardial scar has been clearly expressed through α SMA. In rat myocardial study the expression of α SMA was found in the spindle shaped cells. Through immunohistochemical and histological study, sustained expression of basal lamina protein collagen IV in myocardial scar was absent. It possibly might be due to shorter period of ISO exposure. The appearance of myofibrils persists for at least 4 weeks.

CONCLUSION

The present study demonstrated that the oral pre-treatment with CoQ10 and Magnesium sulphate were associated with moderate protection against ISO-induced cardio toxicity and cardiac hypertrophy. This combination had also shown marked anti lipid per oxidative effect and...
lower myocardial injury by reducing serum markers in stress induced group. Cardio protective effect of the combination was confirmed by the histological study by infarct size quantification assay and histo architectural analysis of the myocardium and through the significant reduction of CK-MB cardiac marker in the group containing both these two drug compared to the stressed group. Whereas other single drug treated group was unable to prove handful of improvement in architectural changes followed by biochemical evidences. The present results can form the basis that combination of CoQ10 and magnesium sulphate proved to be a potential therapeutic agent for pharmacological management of ischemic heart disease. Although the study provided a possible new therapeutic tool for myocardial damage, more studies are required to elucidate and precise the mechanism of CoQ10 and magnesium sulphate in reversing the pathogenesis of myocardial damage.

CONFLICT OF INTEREST
The authors declare that this research does not have any conflict of interest with anyone or any institute.

REFERENCES
23. Indian Pharmacopoeia. Vol-1: Published by Indian Pharmacopoeia commission Ghaziabad; 427-428.
31. www.oxfordbiomed.com


